Clinical study of intravitreal injection of conbercept in preventing postoperative complications of vitrectomy for diabetic retinopathy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047351

Enrollment

Unknown

Registered

2021-06-12

Start date

2021-06-15

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinopathy

Interventions

Group A:Intravitreal injection of conbercept was performed 2 weeks after operation

Group B:No intravitreal injection of conbercept was performed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Stage 4-6 diabetic retinopathy; 2. Need to undergo vitrectomy surgery.

Exclusion criteria

Exclusion criteria: 1. Intraocular injection (anti-VEGF drugs) was performed within 3 months before joining the group; 2. Have performed complete pan-retinal photocoagulation laser treatment; 3. Optic nerve injury, endophthalmitis, primary disease (glaucoma, etc.); 4. Patients with diabetic retinopathy in the degenerative stage of the reproductive membrane.

Design outcomes

Primary

Measure	Time frame
Incidence of vitreous hemorrhage;Incidence of diabetic macular edema;Incidence of neovascular glaucoma;	—

Secondary

Measure	Time frame
Best corrected visual acuity;Intraocular pressure;Silicone oil was removed 12 months after operation;The number of operations for retinal detachment and PPV within 12 months;Intraocular VEGF level;	—

Countries

China

Contacts

Public ContactChen Huijin

chjdoc@alimail.com+86 13641103935

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026